Home › Funds › Pivotal bioVenture Partners Investment Advisor LLC › PCVX

Pivotal bioVenture Partners Investment Advisor LLC position in PCVX

VAXCYTE INC · Health Care

Pivotal bioVenture Partners Investment Advisor LLC reported holding 1,425,470 shares of PCVX (VAXCYTE INC) in its Q3 2026 13F filing — a position valued at US$81.1M, representing 33.06% of its reported portfolio and ranking #1 among its reported holdings. Pivotal bioVenture Partners Investment Advisor LLC has disclosed PCVX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.43M sh
Reported value held$81.11M
Portfolio Weight33.06%
First reportedQ3 2023
Last changeHold
Updated2026-11-14

Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR

How Pivotal bioVenture Partners Investment Advisor LLC's PCVX position evolved

Pivotal bioVenture Partners Investment Advisor LLC first disclosed a stake in PCVX in Q3 2023 at 793,036 shares (US$40.4M). The position peaked in Q2 2026 at 1,425,470 shares, worth US$82.9M. Across 13 filings, Pivotal bioVenture Partners Investment Advisor LLC increased the stake 5 time(s), trimmed it 1 time(s) and left it unchanged 6 time(s). The most recent filing (Q3 2026) shows 1,425,470 shares valued at US$81.1M. Notable position changes include a 84% increase in Q2 2025 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 793.04K $40.43M New
Q4 2023 793.04K $49.80M Hold
Q1 2024 793.04K $54.17M Hold
Q2 2024 793.04K $59.88M Hold
Q3 2024 639.54K $73.08M Reduce
Q4 2024 703.83K $57.62M Add
Q1 2025 710.73K $26.84M Add
Q2 2025 1.31M $42.43M Add
Q3 2025 1.37M $49.43M Add
Q4 2025 1.37M $63.32M Hold
Q1 2026 1.37M $79.75M Hold
Q2 2026 1.43M $82.86M Add
Q3 2026 1.43M $81.11M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About PCVX and 13F data

PCVX (VAXCYTE INC) is a Health Care company. 32 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding PCVX

All PCVX fund holders →

FAQ

How long has Pivotal bioVenture Partners Investment Advisor LLC held PCVX?

Pivotal bioVenture Partners Investment Advisor LLC has disclosed PCVX holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is Pivotal bioVenture Partners Investment Advisor LLC's current position in PCVX?

As of Q3 2026, Pivotal bioVenture Partners Investment Advisor LLC holds 1.43M shares of PCVX (VAXCYTE INC), valued at $81.11M, representing 33.06% of its reported portfolio and ranking #1.

Has Pivotal bioVenture Partners Investment Advisor LLC been buying or selling PCVX?

In the latest 13F filing (Q3 2026), Pivotal bioVenture Partners Investment Advisor LLC held unchanged its position in PCVX. The position peaked in Q2 2026 at 1.43M shares.

Which other funds hold PCVX?

Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 32 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.